Latest news with #kidneydisease
Yahoo
9 hours ago
- Business
- Yahoo
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering will not be subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering as more specifically described in the Offering Document and for gout programs, general corporate and working capital purposes. In connection with the Offering, the Company paid an aggregate of $12,264 in finder's fees and issued, in aggregate, 16,800 finder's warrants. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The issuance of 8,191 Units to an insider of the Company constitutes a 'related party transaction' as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ('MI 61-101'). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company relied on exemptions from the formal valuation and minority shareholder approval requirements, respectively, as neither the fair market value of the Units nor the consideration for such Units, insofar as it involves the insider, exceeds 25 percent of the Company's market capitalization. In other news, the non-brokered private placement that was announced on May 19, 2025 will not proceed. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at For more information, please contact: Allen Davidoff, CEO Nick Rigopulos, Director of Communications adavidoff@ nick@ +1 403 455 7727 +1 617 901 0785 Forward-Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Yahoo
19 hours ago
- Business
- Yahoo
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement
ProKidney Corp. (NASDAQ:PROK) is one of the best high-return penny stocks to buy now. On July 16, the company confirmed the completion of its corporate domestication from the Cayman Islands to the state of Delaware. The change of jurisdiction and related restructuring took effect on July 1, 2025. A scientist wearing a lab coat and safety glasses conducting a research experiment related to biotechnology and kidney diseases. Following the domestication, each of the outstanding Class A and Class B ordinary shares of ProKidney Cayman was converted to one share of Class A or Class B common stock of ProKidney Delaware. In addition, the company amended and restated several material agreements, including the Amended and Restated Tax Receivable Agreement, Lock-Up Agreement, and Exchange Agreement. The domestication comes as the US Food and Drug Administration confirms the use of glomerular filtration rate (eGFR) slope, paving the way for the accelerated approval of the company's kidney disease therapy, rilparencel. The agency also agreed that data from the Phase 3 PROACT 1 trial can be used for both accelerated and full approval pathways. ProKidney Corp. (NASDAQ:PROK) is a late-stage biotechnology company focused on developing a cell therapy called rilparencel (also known as REACT) to treat chronic kidney disease (CKD). Their approach involves using a patient's kidney cells to potentially preserve kidney function and delay or eliminate the need for dialysis. While we acknowledge the potential of PROK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
19 hours ago
- Business
- Yahoo
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment Vafseo, prescribed by over 640 physicians in Q1. A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections. With initial pricing at $15,500 annually and post-TDAPA rates expected near $2,500, Akebia targets a $4–5 billion opportunity by expanding to non-dialysis CKD patients. A pilot launch with a major dialysis provider is set for Q3, covering 75–200 clinics, with broader availability expected in Q4 and a Phase 3 trial planned for later this year. Akebia also reaffirmed strong sales momentum for Auryxia, its existing kidney treatment, despite generic competition. The company's R&D pipeline includes AKB-909O for acute kidney injury and AKB-10108 for retinopathy of prematurity. Akebia aims to position Vafseo as the standard of care across CKD stages, supported by its ongoing VOICE trial targeting reduced hospitalizations. This strategic push underscores Akebia's focus on delivering innovative solutions for chronic kidney care and expanding market reach amid competitive challenges. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. It has two FDA-approved products, Auryxia (ferric citrate) and Vafseo, both of which target complications of kidney disease, such as anemia and hyperphosphatemia. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Health Line
16-07-2025
- Health
- Health Line
Constipation and Chronic Kidney Disease
Chronic kidney disease (CKD) can lead to a variety of digestive symptoms such as loss of appetite, nausea, and diarrhea. For many people, CKD can also lead to constipation. There are a few different reasons why constipation can occur with chronic kidney disease (CKD). Common reasons include: a lack of fiber in diets intended for people with CKD fluid restrictions for people with later-stage CKD co-occurring or secondary conditions medication side effects Treatments, which include lifestyle changes such as eating more fiber and increasing exercise levels, can often help relieve symptoms. This article examines the causes and treatment of constipation in people with CKD and reviews the early symptoms of kidney disease and kidney failure. Constipation isn't typically a symptom of kidney failure. What causes constipation with chronic kidney disease? CKD can lead to constipation for some people. Common causes of constipation for people with kidney disease include: Renal diets It can be difficult enough for people eating a standard American diet to get the fiber they need. People who are on a renal diet are limited in their food choices, and many foods that are high in fiber have traditionally been excluded. However, newer recommendations for people with chronic kidney disease are less strict about fiber-rich foods such as fruits and vegetables, meaning it's safe to add these foods to a renal diet. Co-occurring conditions Many of the conditions that commonly occur alongside kidney disease, such as diabetes, hypothyroidism, and hypercalcemia, can slow down your digestive system. A slow digestive system can lead to constipation. Bacterial imbalance in the gut A bacterial imbalance in the gut, called dysbiosis, can occur when your kidney isn't working correctly. It happens because your kidneys aren't filtering bacteria. This leads to an abnormal mix of bacteria in your intestines, which can cause constipation. Medication reactions People with kidney disease may develop secondary conditions such as gout, anemia, or bone disease. Some of the medications prescribed for these secondary conditions, including blood pressure medications, iron supplements, anti-nausea medications, and calcium supplements, can cause constipation in some people. Fluid restrictions People with later-stage kidney disease may need to restrict their fluid intake, especially those undergoing dialysis. This can make it challenging to get enough hydration to avoid constipation. What's the best way to treat constipation with chronic kidney disease? Treating constipation depends on several factors, but lifestyle and diet changes can often help resolve the condition. Doctors typically recommend starting with lifestyle changes before progressing to medication. Lifestyle treatments that can help people with chronic kidney disease get relief from constipation include: Eating more fiber: Getting enough fiber in your diet is one of the best ways to combat constipation. Fiber helps carry waste through your system. It's found in a variety of foods, including whole grains, nuts, lentils, beans, oats, apples, pears, and vegetables. Increasing your activity: Fitness combats constipation. Exercise helps your blood flow and helps food move through your digestive system. You can start small; even walking a little every day will make a difference. Increasing fluids: Fluids are one of the best ways to beat constipation. People with chronic kidney disease can talk with their doctors about the best way to get enough fluid to keep their digestive systems moving. Try probiotics: Probiotics are live microorganisms that are found in fermented food that can help relieve constipation. Fermented foods included options such as yogurt, sauerkraut, miso, kimchi, tempeh, natto, and homemade pickles. Ask your doctor or dietitian about the right amount of these foods to add to your diet. Relieve symptoms with an over-the-counter (OTC) medication: If your symptoms are severe and haven't been relieved by methods such as hydration or fiber, an OTC medication can help. However, it's important not to take these medications for longer thana few days. OTC options include stool softeners, stimulant laxatives, and fiber supplements. Prescription-strength medications: Your doctor might prescribe prescription versions of any medication if lifestyle changes aren't enough. Biofeedback therapy: Biofeedback therapy is a treatment that retrains the muscles that control bowel movements. How does constipation affect the outlook for people with chronic kidney disease? Constipation can affect the quality of life and outlook for people with CKD. A 2019 study found that constipation can increase the chances of mortality and was linked to a higher risk of serious complications such as end stage renal disease, heart disease, and Parkinson's disease. The study also found that constipation in people with CKD led to a higher risk of developing coronary heart disease and stroke. Is constipation an early warning sign of kidney disease? Constipation isn't typically an early sign of kidney disease. It's more common for kidney disease to cause early symptoms such as: fatigue difficulty concentrating anemia loss of appetite insomnia unexplained muscle cramping sleep apnea red or pink urine urine that appears foamy frequent urinary urges skin that is dry and itchy puffiness around the eyes swollen feet and ankles For people with CKD, what are the symptoms of kidney failure? As kidney disease progresses, it can cause increased symptoms. Some symptoms are similar to early symptoms but are more severe. Other symptoms are unlikely to show up until chronic kidney disease has progressed to kidney failure. Symptoms of kidney failure include: fever fatigue confusion skin rash itchy skin very pale skin weakness unexplained muscle cramping bone pain no urine production or excessive urine production unusual bleeding nose bleeding back pain stomach pain a mass in the stomach diarrhea that is sometimes bloody loss of appetite bad breath a metallic taste in the mouth vomiting that is sometimes severe swelling throughout the body difficulty hearing Takeaway Chronic kidney disease doesn't always cause constipation, but there are a number of reasons why it does for many people with CKD. Renal diets, fluid restrictions, medications, co-occurring disorders, and more can all lead to constipation. Treatment can bring relief and often includes lifestyle changes such as eating more fiber, getting more exercise, and increasing fluids. When these methods aren't enough, medications, biofeedback, and surgery can be options.
Health Line
15-07-2025
- Health
- Health Line
Kidney Function Tests
Key takeaways Kidney function tests are simple blood and urine tests that can identify problems with your kidneys. These tests can estimate your glomerular filtration rate (GFR), which indicates how quickly your kidneys are clearing waste from your body. Your doctor will focus on treating the underlying condition if your tests show early kidney disease. This may include medications, lifestyle changes, or seeing a specialist. Overview of kidney function tests You have two kidneys on either side of your spine that are each approximately the size of a human fist. They're located posterior to your abdomen and below your rib cage. Your kidneys play several vital roles in maintaining your health. One of their most important jobs is to filter waste materials from the blood and expel them from the body as urine. The kidneys also help control the levels of water and various essential minerals in the body. In addition, they're critical to the production of: vitamin D red blood cells hormones that regulate blood pressure If your doctor thinks your kidneys may not be working properly, you may need kidney function tests. These are simple blood and urine tests that can identify problems with your kidneys. You may also need kidney function testing done if you have other conditions that can harm the kidneys, such as diabetes or high blood pressure. They can help doctors monitor these conditions. Symptoms of kidney problems Symptoms that may indicate a problem with your kidneys include: high blood pressure blood in the urine frequent urges to urinate difficulty beginning urination painful urination swelling of the hands and feet due to a buildup of fluids in the body A single symptom may not mean something serious. However, when occurring simultaneously, these symptoms suggest that your kidneys aren't working properly. Kidney function tests can help determine the reason. Types of kidney function tests To test your kidney function, your doctor will order a set of tests that can estimate your glomerular filtration rate (GFR). Your GFR tells your doctor how quickly your kidneys are clearing waste from your body. Urinalysis A urinalysis screens for the presence of protein and blood in the urine. There are many possible reasons for protein in your urine, not all of which are related to disease. Infection increases urine protein, but so does a heavy physical workout. Your doctor may want to repeat this test after a few weeks to see if the results are similar. Your doctor may also ask you to provide a 24-hour urine collection sample. This can help doctors see how fast a waste product called creatinine is clearing from your body. Creatinine is a breakdown product of muscle tissue. Serum creatinine test This blood test examines whether creatinine is building up in your blood. The kidneys usually completely filter creatinine from the blood. A high level of creatinine suggests a kidney problem. According to the National Kidney Foundation (NKF), a creatinine level higher than 1.2 milligrams/deciliter (mg/dL) for women and 1.4 mg/dL for men is a sign of a kidney problem. Blood urea nitrogen (BUN) The blood urea nitrogen (BUN) test also checks for waste products in your blood. BUN tests measure the amount of nitrogen in the blood. Urea nitrogen is a breakdown product of protein. However, not all elevated BUN tests are due to kidney damage. Common medications, including large doses of aspirin and some types of antibiotics, can also increase your BUN. It's important to tell your doctor about any medications or supplements that you take regularly. You may need to stop certain drugs for a few days before the test. A normal BUN level is between 7 and 20 mg/dL. A higher value could suggest several different health problems. Estimated GFR This test estimates how well your kidneys are filtering waste. The test determines the rate by looking at factors, such as: test results, specifically creatinine levels age gender race height weight Any result lower than 60 milliliters/minute/1.73m 2 may be a warning sign of kidney disease. How the tests are performed Kidney function tests usually require a 24-hour urine sample and a blood test. 24-hour urine sample A 24-hour urine sample is a creatinine clearance test. It gives your doctor an idea of how much creatinine your body expels over a single day. On the day that you start the test, urinate into the toilet as you normally would when you wake up. For the rest of the day and night, urinate into a special container provided by your doctor. Keep the container capped and refrigerated during the collection process. Make sure to label the container clearly and to tell other family members why it's in the refrigerator. On the morning of the second day, urinate into the container when you get up. This completes the 24-hour collection process. Follow your doctor's instructions about where to drop the sample off. You may need to return it either to your doctor's office or a laboratory. Blood samples BUN and serum creatinine tests require blood samples taken in a lab or doctor's office. The technician drawing the blood first ties an elastic band around your upper arm. This makes the veins stand out. The technician then cleans the area over the vein. They slip a hollow needle through your skin and into the vein. The blood will flow back into a test tube that will be sent for analysis. You may feel a sharp pinch or prick when the needle enters your arm. The technician will place gauze and a bandage over the puncture site after the test. The area around the puncture may develop a bruise over the next few days. However, you shouldn't feel severe or long-term pain. Treatment of early kidney disease Your doctor will focus on treating the underlying condition if the tests show early kidney disease. Your doctor will prescribe medications to control blood pressure if the tests indicate hypertension. They'll also suggest lifestyle and dietary modifications. If you have diabetes, your doctor may want you to see an endocrinologist. This type of doctor specializes in metabolic diseases and can help ensure that you have the best blood glucose control possible. If there are other causes of your abnormal kidney function tests, such as kidney stones and excessive use of painkillers, your doctor will take appropriate measures to manage those disorders.
